Gastroenterology
Volume 139, Issue 3 , Pages 836-845.e1 , September 2010

Genetic Covariance Between γ-Glutamyl Transpeptidase and Fatty Liver Risk Factors: Role of β2-Adrenergic Receptor Genetic Variation in Twins

Received 21 June 2009 ,Accepted 1 June 2010.

References 

  1. Ruttenburg AM, Goldbarg JA, Pineda EP. Serum gamma-glutamyl transpeptidase activity in hepatobiliary pancreatic disease. Gastroenterology. 1963;45:43–48
  2. Nemesanszky E, Lott JA. Gamma-glutamyltransferase and its isoenzymes: progress and problems. Clin Chem. 1985;31:797–803
  3. Irie M, Suzuki N, Sohda T, et al. Hepatic expression of gamma-glutamyltranspeptidase in the human liver of patients with alcoholic liver disease. Hepatol Res. 2007;37:966–973
  4. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38:263–355
  5. Ikai E, Honda R, Yamada Y. Serum gamma-glutamyl transpeptidase level and blood pressure in nondrinkers: a possible pathogenetic role of fatty liver in obesity-related hypertension. J Hum Hypertens. 1994;8:95–100
  6. Ikai E, Noborizaka Y, Tsuritani I, Honda R, Ishizaki M, Yamada Y. Serum gamma-glutamyl transpeptidase levels and hypertension in non-drinkers: a possible role of fatty liver in the pathogenesis of obesity related hypertension. Obes Res. 1993;1:469–474
  7. Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27:127–133
  8. Jo SK, Lee WY, Rhee EJ, et al. Serum gamma-glutamyl transferase activity predicts future development of metabolic syndrome defined by 2 different criteria. Clin Chim Acta. 2009;403:234–240
  9. Jo SK, Lee WY, Rhee EJ, et al. Serum gamma-glutamyl transferase activity predicts future development of metabolic syndrome defined by 2 different criteria. Clin Chim Acta. 2009;403(1–2):234–240
  10. Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg. 2006;16:1278–1286
  11. Lee DH, Jacobs DR, Gross M, et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2003;49:1358–1366
  12. Saely CH, Vonbank A, Rein P, et al. Alanine aminotransferase and gamma-glutamyl transferase are associated with the metabolic syndrome but not with angiographically determined coronary atherosclerosis. Clin Chim Acta. 2008;397:82–86
  13. Yamada J, Tomiyama H, Yambe M, et al. Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome. Atherosclerosis. 2006;189:198–205
  14. Rao F, Zhang L, Wessel J, et al. Tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis: discovery of common human genetic variants governing transcription, autonomic activity, and blood pressure in vivo. Circulation. 2007;116:993–1006
  15. Wessel J, Moratorio G, Rao F, et al. C-reactive protein, an ‘intermediate phenotype’ for inflammation: human twin studies reveal heritability, association with blood pressure and the metabolic syndrome, and the influence of common polymorphism at catecholaminergic/beta-adrenergic pathway loci. J Hypertens. 2007;25:329–343
  16. Bao X, Mills PJ, Rana BK, et al. Interactive effects of common beta2-adrenoceptor haplotypes and age on susceptibility to hypertension and receptor function. Hypertension. 2005;46:301–307
  17. Iwamoto N, Ogawa Y, Kajihara S, et al. Gln27Glu beta2-adrenergic receptor variant is associated with hypertriglyceridemia and the development of fatty liver. Clin Chim Acta. 2001;314:85–91
  18. Vardeny O, Detry MA, Moran JJ, Johnson MR, Sweitzer NK. The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker. J Cardiovasc Pharmacol. 2008;52:500–506
  19. Isaza CA, Henao J, Sanchez JC, Porras GL, Cardona J, Bedoya G. Beta-2-adrenergic receptor polymorphisms and changes in lipids induced by metoprolol. Pharmacology. 2007;80:279–285
  20. Svetkey LP, Timmons PZ, Emovon O, Anderson NB, Preis L, Chen YT. Association of hypertension with beta2- and alpha2c10-adrenergic receptor genotype. Hypertension. 1996;27:1210–1215
  21. Patton HM, Lavine JE, Van Natta ML, Schwimmer JB, Kleiner D, Molleston J. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology. 2008;135:1961–1971e1962
  22. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573–577
  23. Zhang L, Rao F, Zhang K, et al. Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk. J Clin Invest. 2007;117:2658–2671
  24. Zhang L, Rao F, Wessel J, et al. Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in tyrosine hydroxylase: prediction of catecholamines and response to stress in twins. Physiol Genomics. 2004;19:277–291
  25. Brinton TJ, Kailasam MT, Wu RA, et al. Arterial compliance by cuff sphygmomanometer (Application to hypertension and early changes in subjects at genetic risk). Hypertension. 1996;28:599–603
  26. Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A. 2000;97:10483–10488
  27. McGraw DW, Forbes SL, Kramer LA, Liggett SB. Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest. 1998;102:1927–1932
  28. Buetow KH, Edmonson M, MacDonald R, et al. High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci U S A. 2001;98:581–584
  29. Goldbarg JA, Pineda EP, Smith EE, Friedman OM, Rutenburg AM. A method for the colorimetric determination of gamma-glutamyl transpeptidase in human serum; enzymatic activity in health and disease. Gastroenterology. 1963;44:127–133
  30. Halperin E, Eskin E. Haplotype reconstruction from genotype data using Imperfect Phylogeny. Bioinformatics. 2004;20:1842–1849
  31. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–265
  32. Johnatty SE, Abdellatif M, Shimmin L, Clark RB, Boerwinkle E. Beta 2 adrenergic receptor 5' haplotypes influence promoter activity. Br J Pharmacol. 2002;137:1213–1216
  33. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA. 2005;294:1526–1533
  34. Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol. 2003;43:381–411
  35. Oben JA, Yang S, Lin H, Ono M, Diehl AM. Norepinephrine and neuropeptide Y promote proliferation and collagen gene expression of hepatic myofibroblastic stellate cells. Biochem Biophys Res Commun. 2003;302:685–690
  36. Oben JA, Roskams T, Yang S, et al. Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut. 2004;53:438–445
  37. Oben JA, Roskams T, Yang S, et al. Norepinephrine induces hepatic fibrogenesis in leptin deficient ob/ob mice. Biochem Biophys Res Commun. 2003;308:284–292
  38. O'Riordain MG, Ross JA, Fearon KC, et al. Insulin and counterregulatory hormones influence acute-phase protein production in human hepatocytes. Am J Physiol. 1995;269:E323–E330
  39. Li Z, Oben JA, Yang S, et al. Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis. Hepatology. 2004;40:434–441
  40. Oben JA, Roskams T, Yang S, et al. Sympathetic nervous system inhibition increases hepatic progenitors and reduces liver injury. Hepatology. 2003;38:664–673
  41. Van Heeswijk JC, Vianen GJ, van den Thillart GE. The adrenergic control of hepatic glucose and FFA metabolism in rainbow trout (Oncorhynchus mykiss): increased sensitivity to adrenergic stimulation with fasting. Gen Comp Endocrinol. 2006;145:51–61
  42. Hargrove DM, Bagby GJ, Lang CH, Spitzer JJ. Adrenergic blockade prevents endotoxin-induced increases in glucose metabolism. Am J Physiol. 1988;255:E629–E635
  43. National Health and Nutrition Examiniation Survey 1999-2002. http://www.cdc.gov/nchs/nhanes.htmAccessed August 4, 2010
  44. Whitfield JB, Zhu G, Nestler JE, Heath AC, Martin NG. Genetic covariation between serum gamma-glutamyltransferase activity and cardiovascular risk factors. Clin Chem. 2002;48:1426–1431
  45. Rahmioglu N, Andrew T, Cherkas L, et al. Epidemiology and genetic epidemiology of the liver function test proteins. PLoS ONE. 2009;4:e4435
  46. Lin JP, O'Donnell CJ, Fox CS, Cupples LA. Heritability of serum gamma-glutamyltransferase level: genetic analysis from the Framingham Offspring Study. Liver Int. 2009;29:776–777
  47. Yuan X, Waterworth D, Perry JR, et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet. 2008;83:520–528
  48. Bathum L, Petersen HC, Rosholm JU, Hyltoft Petersen P, Vaupel J, Christensen K. Evidence for a substantial genetic influence on biochemical liver function tests: results from a population-based Danish twin study. Clin Chem. 2001;47:81–87
  49. Valle A, O'Connor DT, Taylor P, et al. Butyrylcholinesterase: association with the metabolic syndrome and identification of 2 gene loci affecting activity. Clin Chem. 2006;52:1014–1020
  50. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–1465
  51. Wilson PA, Gardner SD, Lambie NM, Commans SA, Crowther DJ. Characterization of the human patatin-like phospholipase family. J Lipid Res. 2006;47:1940–1949
  52. Jocken JW, Langin D, Smit E, et al. Adipose triglyceride lipase and hormone-sensitive lipase protein expression is decreased in the obese insulin-resistant state. J Clin Endocrinol Metab. 2007;92:2292–2299
  53. Ryden M, Jocken J, van Harmelen V, et al. Comparative studies of the role of hormone-sensitive lipase and adipose triglyceride lipase in human fat cell lipolysis. Am J Physiol Endocrinol Metab. 2007;292:E1847–E1855
  54. Mulder H, Sorhede-Winzell M, Contreras JA, et al. Hormone-sensitive lipase null mice exhibit signs of impaired insulin sensitivity whereas insulin secretion is intact. J Biol Chem. 2003;278:36380–36388
  55. Day CP. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int. 2006;26:1021–1028
  56. Speliotes EK. Genetics of common obesity and nonalcoholic fatty liver disease. Gastroenterology. 2009;136:1492–1495
  57. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis. 2007;27:44–54
  58. Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med. 1981;305:1371–1374
  59. Pascal JP, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med. 1987;317:856–861
  60. Turnes J, Hernandez-Guerra M, Abraldes JG, et al. Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. Hepatology. 2006;43:34–41

 View this article's video abstract at www.gastrojournal.org

 Conflicts of interest The authors disclose no conflicts.

 Funding This work was supported in part by the National Institutes of Health grants to Daniel T. O'Connor, MD, and an American Gastroenterological Association Foundation, Sucampo, ASP Designated Research Scholar Award in Geriatric Gastroenterology (supported by a T. Franklin Williams Scholarship Award; Funding provided by: Atlantic Philanthropies, Inc, the John A. Hartford Foundation, the Association of Specialty Professors, and the American Gastroenterological Association) to Rohit Loomba, MD, MHSc. Role of funding agencies: Funding agencies did not have any role in the design and conduct of the study, collection, management, analysis and interpretation of the data; preparation, review, or approval of the manuscript.

PII: S0016-5085(10)00863-2

doi: 10.1053/j.gastro.2010.06.009

Gastroenterology
Volume 139, Issue 3 , Pages 836-845.e1 , September 2010

Article Tools

* Image Usage & Resolution